- Home
- NTSK vs ARWR Comparison
NTSK vs ARWR Comparison
Compare NTSK & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTSK | ARWR |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 7.0B |
| IPO Year | 2025 | 2009 |
Fundamental Metrics
Financial Performance| Metric | NTSK | ARWR |
|---|---|---|
| Price | $21.55 | $47.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 15 |
| Target Price | $20.82 | ★ $106.71 |
| AVG Volume (30 Days) | ★ 6.1M | 1.8M |
| Earning Date | 12-02-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.64 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $708,997,000.00 | $16,142,321.00 |
| Revenue This Year | $25.60 | N/A |
| Revenue Next Year | $21.15 | $112.40 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 31.72 | N/A |
| 52 Week Low | $7.67 | $37.06 |
| 52 Week High | $26.71 | $95.49 |
Technical Indicators
Market Signals| Indicator | NTSK | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 49.79 | 22.07 |
| Support Level | $20.73 | N/A |
| Resistance Level | $26.71 | $66.37 |
| Average True Range (ATR) | 1.71 | 2.84 |
| MACD | -0.40 | -0.87 |
| Stochastic Oscillator | 16.64 | 15.96 |
Price Performance
Historical ComparisonAbout NTSK Netskope Inc.
Netskope Inc is redefining the security and networking of cloud and AI. The company has formed a cloud-native platform that offers converged security, networking services, and analytics technology stack to enable fast and secure AI, cloud, and web access at the edge. The products of the company include Netskope One SASE, Netskope One SSE, Cloud Access Security Broker (CASB), Next Generation Secure Web Gateway (SWG), Private Access, Cloud Firewall, SD-WAN, SkopeAI, and others.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.